Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-07-24
2007-07-24
Habte, Kahsay (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S071000, C544S092000
Reexamination Certificate
active
10946476
ABSTRACT:
Compounds having the structure of formula I are provided. In formula I, R1is H, OH, substituted or unsubstituted C1to C3alkyl, C1to C3perfluoroalkyl, or COR6; R6is H, substituted or unsubstituted C1to C4alkyl, aryl, substituted or unsubstituted C1to C4alkoxy, substituted or unsubstituted C1to C3aminoalkyl; R2and R3are H, substituted or unsubstituted C1to C6alkyl, C1to C6perfluoroalkyl, substituted or unsubstituted C2to C6alkenyl, substituted or unsubstituted C2to C6alkynyl, substituted or unsubstituted C3to C6cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclic; or R2and R3are fused to form spirocyclic rings; R4is NHR7, OR7, NHSO2R7, or OSO2R7; Q is O, S, NR8, or CR9R10; or a pharmaceutically acceptable salt, ester, or prodrug thereof. Such compounds are useful as progesterone receptor modulators and for treating progesterone receptor related conditions.
REFERENCES:
patent: 5719136 (1998-02-01), Chwalisz et al.
patent: 5874430 (1999-02-01), Christ et al.
patent: 6306851 (2001-10-01), Santilli et al.
patent: 6339098 (2002-01-01), Collins et al.
patent: 6355648 (2002-03-01), Fensome et al.
patent: 6358948 (2002-03-01), Zhang et al.
patent: 6369056 (2002-04-01), Zhang et al.
patent: 6380235 (2002-04-01), Zhang et al.
patent: 6391907 (2002-05-01), Fensome et al.
patent: 6407101 (2002-06-01), Collins et al.
patent: 6417214 (2002-07-01), Ullrich et al.
patent: 6436929 (2002-08-01), Zhang et al.
patent: 6441019 (2002-08-01), Santilli et al.
patent: 6509334 (2003-01-01), Zhang et al.
patent: 6521657 (2003-02-01), Fensome et al.
patent: 6583145 (2003-06-01), Fensome et al.
patent: 6608068 (2003-08-01), Fensome et al.
patent: 6693103 (2004-02-01), Zhang et al.
patent: 2002/0169198 (2002-11-01), Fensome et al.
patent: 2003/0092711 (2003-05-01), Zhang et al.
patent: 2003/0225109 (2003-12-01), Fensome et al.
patent: WO00/66555 (2000-11-01), None
patent: WO00/66556 (2000-11-01), None
patent: WO00/66560 (2000-11-01), None
patent: WO00/66564 (2000-11-01), None
patent: WO00/66570 (2000-11-01), None
patent: WO00/66591 (2000-11-01), None
patent: WO00/66592 (2000-11-01), None
patent: WO016108 (2001-03-01), None
Wolff Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
John Wiebe, Endocrine-Related Cancer (2006) 13, 717-738.
Hamann et al, Synthesis and Biological Activity of Novel Nonsteroidal Progesterone Receptor Antagonists, Annals New York Academy of Sciences, 761, pp. 382-387, (1995).
Kurihara et al, Synthesis of (±)-PF1092A, B, C; New Nonsteroidal Progesterone Receptor Ligands, The Journal of Antibiotics, vol. 50, No. 4, pp. 360-362, (Apr. 1997).
Perlman et al, 20-Oxopregnacalciferols: Vitamin D Compounds that bind the Progesterone Receptor, Tetrahedron Letters, vol. 35, No. 15, pp. 2295-2298, (1994).
Combs et al, Nonsteroidal Progesterone Receptor Ligands. 2. High-Affinity Ligands with Selectivity for Bone cell Progesterone Receptors, Journal of Medicinal Chemistry, vol. 38, No. 25, (1995).
Tegley et al, 5-Benzylidene 1,2-Dihydrochromeno[3,4-f]Quinolines, A Novel Class of nonsteroidal Human Progesterone Receptor Agonists, J. Med. Chem., 41, pp. 4354-4359, (1998).
Zhi et al, Nonsteroidal Progesterone Receptor Antagonists based on 6-Thiophenehydroquinolines, Bioorg. Med. Chem. Lett. 10, pp. 415-418, (2000).
Michna et al, Differentiation Therapy with Progesterone Antagonists, Ann. N.Y. Acad. Sci. 761, 224, (1995).
Kettel et al, Endocrine Responses to Long-Term Administration of the Antiprogesterone RU486 in Patients with Pelvic Endometriosis, Fertility and Sterility, vol. 56, No. 3, (Sep. 1991).
Murphy et al, Regression of Uterine Leiomyomata in Response to the Antiprogesterone RU 486, Journal of Clinical Endocrinology and Metabolism, vol. 76, No. 2, pp. 513-517, (1993).
Horowitz et al, Progestins, Progesterone Receptors, and Breast Cancer, SciFinder, pp. 1-2, Abstract, (Mar. 10, 1998).
Kekkonen et al, Sequential Regimen of the Antiprogesterone RU486 and Synthetic Progestin for Contraception, Fertility and Sterility, vol. 60, 610, No. 4, (Oct. 1993).
Ulmann et al, Clinical Uses of Mifepristone (MFP), Ann. N.Y. Acad. Sci., 261, 248, (1995).
Mangelsdorf et al, The Nuclear Receptor Superfamily: The Second Decade, Cell, vol. 83, pp. 835-839, (Dec. 15, 1995).
Zhi et al, 5-Aryl-1,2-dihydrochromeno[3,4-f]Quinolines: A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists, J. Med. Chem.. 41(3):291-302, (Jan. 29, 1998).
Kern Jeffrey
Zhang Puwen
Habte Kahsay
Howson & Howson LLP
Milowsky Arnold S.
Wyeth
LandOfFree
6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3773169